You can buy or sell Tricida and other stocks, options, ETFs, and crypto commission-free!
Tricida, Inc. Common Stock, also called Tricida, is a pharmaceutical company, which focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. Read More The company was founded by Gerrit Klaerner and Craig Jon Hawker in 2013 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Seeking AlphaMay 12
Tricida, Inc. CEO Gerrit Klaerner on Q1 2019 Results - Earnings Call Transcript
Tricida, Inc. (NASDAQ:TCDA) Q1 2019 Results Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Jackie Cossmon - IR Gerrit Klaerner - CEO, President & Founder Geoff Parker - CFO Conference Call Participants Yuko Oku - JP Morgan Phil Nadeau - Cowen and Company Operator Good day, ladies and gentlemen. Thank you for standing by and welcome to the Tricida First Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later ,we will condu...
The Motley FoolMay 8
Tricida, Inc. (TCDA) Q1 2019 Earnings Call Transcript
Tricida, Inc. (NASDAQ:TCDA) Q1 2019 Earnings Call May 8, 2019, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen. Thank you for standing by and welcome to the Tricida first quarter 2019 financial results conference call. At this time, all participants on a listen-only mode. Later, we'll conduct a question-and-answer session, instruction for that time. If you should require any assistance in the call, please pres...
Yahoo FinanceMay 8
Tricida Announces First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three months ended March 31, 2019 and provided an update on key initiatives. Recent Highlights Completed a follow-...
Expected Aug 7, After Hours